Pacira BioSciences, Inc. (PCRX)

Market Cap	1.44B
Revenue (ttm)	681.75M
Net Income (ttm)	70.47M
Shares Out	46.55M
EPS (ttm)	1.45
PE Ratio	21.26
Forward PE	10.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,820
Open	31.56
Previous Close	31.51
Day's Range	30.70 - 31.67
52-Week Range	25.33 - 42.63
Beta	0.77
Analysts	Strong Buy
Price Target	47.40 (+53.8%)
Earnings Date	May 7, 2024

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and sup...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 712
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX

Financial Performance

In 2023, PCRX's revenue was $674.98 million, an increase of 1.22% compared to the previous year's $666.82 million. Earnings were $41.96 million, an increase of 163.72%.

Analyst Forecast

According to 10 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price forecast is $47.4, which is an increase of 53.80% from the latest price.

Price Target

$47.4

(53.80% upside)

Analyst Consensus: Strong Buy